LoQus23 Therapeutics

LoQus23 Therapeutics is discovering oral small molecule therapies that block somatic expansion to slow or halt disease progression in Huntington’s and other chronic diseases.

The team at LoQus23 is taking a structure-based approach to identifying small molecule allosteric inhibitors of MutSβ to stop DNA instability and therefore slow neurodegeneration in Huntington’s disease, myotonic dystrophy type 1 and other triplet repeat expansion diseases.

Oral, small molecule drugs have a strong track record in treating complex brain diseases and provide greater convenience for patients compared with other, more complex, treatment approaches.